What does the future hold for cell-based tolerogenic therapy?

Nature Reviews Immunology

Volumn 7, Issue 8, 2007, Pages 650-654

  Bluestone, Jeffrey A ^a   Thomson, Angus W ^b   Shevach, Ethan M ^c   Weiner, Howard L ^d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DENDRITIC CELL VACCINE; GLUCOCORTICOID; INTERLEUKIN 7 RECEPTOR; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL THERAPY; DENDRITIC CELL; DRUG SAFETY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSDUCTION; GOOD MANUFACTURING PRACTICE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; MUCOSAL IMMUNITY; MULTIPLE SCLEROSIS; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; SOMATIC GENE THERAPY; SUICIDE GENE; T LYMPHOCYTE ACTIVATION; THROMBOCYTE TRANSFUSION;

ANIMALS; AUTOIMMUNE DISEASES; FORECASTING; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES, REGULATORY;

EID: 34547150491     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2137     Document Type: Review

References (0)